MarketCap
Facebook
X
Telegram
Intellia Therapeutics Market Cap | NTLA
As of October 26, 2026 Intellia Therapeutics has a market cap of $ 1.21 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Intellia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 776 M | 1.08 B | 2.43 B | 2.98 B | 6.7 B | 3.51 B | 563 M | 593 M | 935 M | 279 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.7 B | 279 M | 1.99 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Theravance Biopharma
TBPH
|
742 M | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
Cocrystal Pharma
COCP
|
11.4 M | $ 0.99 | 4.32 % | $ 11.2 M |  USA |
 |
Collegium Pharmaceutical
COLL
|
1.4 B | $ 23.27 | 1.35 % | $ 737 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
3.75 B | $ 87.62 | 2.04 % | $ 9.1 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 4.03 | -0.5 % | $ 53.7 M | USA |
 |
CorMedix
CRMD
|
456 K | $ 8.01 | 1.91 % | $ 577 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
4.39 B | $ 48.85 | -1.1 % | $ 4.39 B |  Schweiz |
 |
Champions Oncology
CSBR
|
83.8 M | $ 4.8 | 1.69 % | $ 66.4 M | USA |
 |
CytomX Therapeutics
CTMX
|
931 M | $ 2.23 | -3.88 % | $ 308 M | USA |
 |
CEL-SCI Corporation
CVM
|
19.9 M | $ 1.54 | -5.52 % | $ 12.3 M | USA |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
49.1 M | - | -10.95 % | $ 876 K | USA |
 |
Cytokinetics, Incorporated
CYTK
|
7.55 M | $ 61.14 | -0.16 % | $ 7.34 M | USA |
 |
ChemoCentryx
CCXI
|
1.88 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.82 B | $ 9.91 | 1.64 % | $ 1.38 B |  France |
 |
Zosano Pharma Corporation
ZSAN
|
52.7 M | - | 7.23 % | $ 2.72 M | USA |
 |
Spectrum Pharmaceuticals
SPPI
|
123 M | - | - | $ 189 M | USA |
 |
C4 Therapeutics
CCCC
|
234 M | $ 2.99 | -2.28 % | $ 248 M | USA |
 |
VBI Vaccines
VBIV
|
9.65 M | - | -50.87 % | $ 1.09 M | USA |
 |
Certara
CERT
|
1.08 B | $ 10.47 | 1.36 % | $ 1.68 B | USA |
 |
Precision BioSciences
DTIL
|
64.6 M | $ 6.45 | -2.86 % | $ 82.7 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
551 M | - | - | $ 1.2 B | USA |
 |
Decibel Therapeutics
DBTX
|
102 M | - | - | $ 123 M | USA |
 |
Dyadic International
DYAI
|
31.5 M | $ 0.43 | 7.74 % | $ 15.6 M | USA |
 |
IVERIC bio
ISEE
|
2.97 B | - | - | $ 5.51 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
43.9 M | $ 0.17 | -1.38 % | $ 7.77 M |  Israel |
 |
Myovant Sciences Ltd.
MYOV
|
1.4 B | - | -0.04 % | $ 2.62 B | USA |
 |
Enanta Pharmaceuticals
ENTA
|
259 K | $ 11.88 | 2.06 % | $ 253 K | USA |
 |
Entera Bio Ltd.
ENTX
|
89.6 M | $ 2.89 | -1.03 % | $ 133 M | Israel |
 |
Exelixis
EXEL
|
11.7 B | $ 65.03 | 0.77 % | $ 17.7 B | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
1.15 M | $ 0.37 | -7.54 % | $ 27.1 K | USA |
 |
Fortress Biotech
FBIO
|
77.8 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
291 M | $ 1.27 | -4.51 % | $ 108 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
169 M | $ 10.13 | 0.5 % | $ 289 M | USA |
 |
Metacrine
MTCR
|
13.5 M | - | - | $ 24.2 M | USA |
|
Foghorn Therapeutics
FHTX
|
356 M | $ 2.03 | 1.25 % | $ 128 M | USA |
|
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Molecular Templates
MTEM
|
10.1 M | - | -23.43 % | $ 495 K | USA |
 |
CohBar
CWBR
|
5.31 M | - | -15.44 % | $ 2.2 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
1.2 B | - | - | $ 2.18 B | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
73.7 M | - | - | $ 105 M | USA |
 |
Global Blood Therapeutics
GBT
|
1.82 B | - | - | $ 4.62 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
1.4 M | - | -23.04 % | $ 26.6 M | USA |
 |
Infinity Pharmaceuticals
INFI
|
17 M | - | -46.98 % | $ 3.57 M | USA |
 |
NanoString Technologies
NSTG
|
459 M | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
12.5 M | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
746 M | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
40.7 M | - | - | $ 59.7 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |